Scarica l'app Stockscreener
12.22
3.82%
0.45
Precedente Chiudi:
$11.77
Aprire:
$11.81
Volume 24 ore:
1.02M
Relative Volume:
0.70
Capitalizzazione di mercato:
$892.80M
Reddito:
-
Utile/perdita netta:
$-148.00M
Rapporto P/E:
-2.7585
EPS:
-4.4299
Flusso di cassa netto:
$-135.66M
1 W Prestazione:
+0.33%
1M Prestazione:
+31.68%
6M Prestazione:
+43.26%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$11.44
$12.26
Intervallo di 1 settimana:
$11.26
$12.26
Portata 52W:
$3.76
$14.35
Helus Pharma Inc Stock (HELP) Company Profile
Nome
Helus Pharma Inc
Settore
Industria
Telefono
-
Indirizzo
-
Compare HELP vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
HELP
Helus Pharma Inc
|
12.22 | 911.06M | 0 | -148.00M | -135.66M | -4.4299 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Helus Pharma Inc Stock (HELP) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-13 | Iniziato | TD Cowen | Buy |
| 2026-02-02 | Iniziato | Jefferies | Buy |
| 2025-03-13 | Iniziato | Guggenheim | Buy |
| 2021-11-19 | Downgrade | Maxim Group | Buy → Hold |
Helus Pharma Inc Borsa (HELP) Ultime notizie
Helus Pharma advances psychedelic treatments fo... - Pluang
Helus Pharma: An Undervalued Psychedelic Platform Approaching A Major Catalyst - Seeking Alpha
Cybin Stock Advances 5.23% as Phase 3 Depression Program, Leadership Expansion and Late-Stage Catalysts Lift Optimism - kalkine.ca
symbol__ Stock Quote Price and Forecast - CNN
HELP Stock Jumps 6% After TD Cowen Hikes Target Nearly 8x To $62 - Yahoo Finance
HELP Maintained by TD Cowen -- Price Target Raised to $62 - GuruFocus
TD Cowen raises Helus Pharma stock price target to $62 on trial timing - Investing.com Canada
Cybin (NYSE: HELP) plans 1.18M RSUs with first sale in 2026 - Stock Titan
Cybin Inc. (HELP) sets performance share plan through 2029 - Stock Titan
Helus Pharma stock rating reiterated at Buy by H.C. Wainwright - Investing.com Canada
Cybin (HELP) execs granted $12.6M shares as holders face 82% loss - Stock Titan
Helus Pharma Strengthens Leadership with Key Appointments as Pipeline Advances - citybuzz -
Cybin (HELP) adds exhibit to its base shelf registration - Stock Titan
How Helus’ new CEO plans to scale its psychedelic drug pipeline - Pharma Voice
Helus Pharma appoints former Intra-Cellular executives By Investing.com - Investing.com Canada
Helus Pharma Appoints Regina Donohue as Chief People Officer and Suresh Durgam, M.D., to its Scientific Advisory BoardTue, 08/18/202607:30 - Helus Pharma
Helus Pharma Inc (HELP) Q1 2026 Results Highlight Unprofitable S - GuruFocus
Helus Pharma Q1 Results: Net loss widens to $47.8M, cash at $166.4M - scanx.trade
Sirenia Capital (HELP) reports 3.03M-share Cybin stake including warrant shares - Stock Titan
Cybin : MDA Q1 27 FINAL - marketscreener.com
Cybin : Financial Statements Q1 27 FINAL - marketscreener.com
Helus Pharma (HELP) pushes Phase 3 depression and anxiety drug programs while managing cash needs - Stock Titan
Helus Pharma Appoints Michael Halstead CEO, Completes Enrollment in Phase 3 APPROACH Study of HLP003 and Reports Q2 2026 Results - Quiver Quantitative
Canada's Helus Pharma Q1 loss widens as R&D spending rises - TradingView
Helus Pharma Reports First Quarter Fiscal 2027 Financial Results and Recent Business HighlightsFri, 08/14/202607:28 - ir.helus.com
Helus Pharma finishes Phase 3 depression trial enrollment - Stock Titan
Cybin Conference: Helus CEO Eyes Q4 Phase III Depression Data for HLP003 - MarketBeat
Helus Pharma (CN: HELP) Names New CEO as Pivotal Depression Trial Nears Its Finish Line - kalkine.ca
HELP Stock Price and Chart — NEO:HELP - TradingView
Cybin Stock Builds Bullish Momentum as Clinical Catalysts Strengthen the HELP Outlook - kalkine.ca
Helus Pharma at Canaccord Genuity growth conference: phase iii test looms - Investing.com Nigeria
Adage Capital reports 5.29% Cybin Inc. (HELP) ownership, 3.29M shares - stocktitan.net
Cybin D/B/A Helus Pharma (HELP.NE) stock price, news, quote and history - Yahoo Finance UK
Cybin D/B/A Helus Pharma (HELP) Stock Price, News, Quote & History - Yahoo! Finance Canada
FDA Fast-Tracks Psychedelic Research After Trump’s Executive Order — CMPS, HELP Stocks Gain - Stocktwits
Helus Pharma (HELP) CEO to Join Canaccord Genuity Growth Conference Fireside Chat - Stock Titan
Cybin’s Helus Pharma to join Canaccord Genuity Annual Growth Conference fireside chat - Bitget
Helus Pharma to Participate at the Canaccord Genuity 46th Annual Growth Conference in Boston - investingnews.com
Cybin (HELP) Names New CEO, Is The Stock Still Cheap? - Yahoo! Finance Canada
Cybin (HELP) Is Up 33.1% After Hiring Helus Veteran Michael Halstead As CEO – Has The Bull Case Changed? - Yahoo Finance
Cybin (Helus Pharma, HELP) Leaps 14% Ahead of Pivotal Depression Trial Data - kalkine.ca
Could Helus Pharma’s New CEO Reframe Cybin’s (HELP) Path From Clinical Trials To Commercial Scale? - simplywall.st
Helus Pharma Shares Rise After Appointing New CEO - Moomoo
A CEO With a Proven Track Record of Success in Growing and Scaling Biopharmaceutical Companies Just Appointed CEO at a Clinical-Stage Biotech, Months Before Its Pivotal Phase 3 Readout - The Manila Times
A CEO With a Proven Track Record of Success in Growing and Scaling Biopharmaceutical Companies ... - caledonianrecord.com
A CEO With a Proven Track Record of Success in Growing and - GlobeNewswire
Helus Pharma appoints Michael Halstead as chief executive - Investing.com
Helus Pharma Appoints Michael Halstead as Chief Executive Officer - The Manila Times
Helus Pharma appoints Michael Halstead as chief executive By Investing.com - Investing.com India
Helus Pharma Appoints Former Intra-Cellular Therapies President Michael Halstead as CEO Ahead of Key HLP003 Phase 3 Readout - Quiver Quantitative
HELP Initiated Coverage by Wells Fargo -- Rating Set to Overweig - GuruFocus
Helus Pharma Inc Azioni (HELP) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.86%
0.31%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):